1. Щелканов М.Ю., Колобухина Л.В., Львов Д.К. Коронавирусы человека (Nidovirales, Coronaviridae): возросший уровень эпидемической опасности. Лечащий врач. 2013;(10):49–55. Режим доступа: https://www.lvrach.ru/2013/10/15435832.
2. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of anovel coronavirus from aman with pneumoniain Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820. doi: 10.1056/NEJMoa1211721.
3. De Groot R.J., Baker S.C., Baric R.S., Brown C.S., Drosten C., Enjuanes L. et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group. J Virol. 2013;87(14):7790–7792. doi: 10.1128/JVI.01244-13.
4. Жиленко В.Ю. Анализ влияния пандемии COVID-19 на экономику России. В: Актуальные проблемы менеджмента, экономики и экономической безопасности: материалы II Международной научной конференции. Костанай, 28–30 сентября 2020 г. Чебоксары: Среда; 2020, С. 66–70. Режим доступа: https://phsreda.com/cv/article/96394/discussion_platform.
5. Sun P., Lu X., Xu C., Sun W., Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548–551. doi: 10.1002/jmv.25722.
6. Jiang F., Deng L., Zhang L., Cai Y., Cheung C.W., Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;25(5):1545–1549. doi: 10.1007/s11606-020-05762-w.
7. Canna S.W., Behrens E.M. Making sense of the cytokine storm: A conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am. 2012;59(2):329–344. doi: 10.1016/j.pcl.2012.03.002.
8. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–151. (In Chinese) doi: 10.3760/cma.j.issn.0254-6450.2020.02.003.
9. Mehra M.R., Ruschitzka F., Patel A.N. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820. doi: 10.1016/S0140-6736(20)31324-6.
10. Alhazzani W., Møller M.H., Arabi Y.M., Loeb M., Gong M.N., Fan E. et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020;48(6):e440–e469. doi: 10.1097/CCM.0000000000004363.
11. Салухов В.В., Ковалевская Е.А., Курбанова В.В. Костные и внекостные эффекты витамина D, а также возможности медикаментозной коррекции его дефицита. Медицинский совет. 2018;(4):90–99. doi: 10.21518/2079-701X-2018-4-90-99.
12. Cannell J.J., Vieth R., Umhau J.C., Holick M.F., Grant W.B., Madronich S. et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134(6):1129– 1140. doi: 10.1017/S0950268806007175.
13. Nam H.H., Ison M.G. Respiratory syncytial virus infection in adults. BMJ. 2019;366:l5021. doi: 10.1136/bmj.l5021.
14. Feng X., Guo T., Wang Y., Kang D., Che X., Zhang H. et al. The vitamin D status and its e ects on life quality among the elderly in Jinan, China. Arch Gerontol Geriatr. 2016;62:26–29. doi: 10.1016/j.archger.2015.09.002.
15. Nassar M.S., Bakhrebah M.A., Meo S.A., Alsuabeyl M.S., Zaher W.A. Global seasonal occurrence of middle east respiratory syndrome coronavirus (MERS-CoV) infection. Eur Rev Med Pharmacol Sci. 2018;22(12):3913–3918. doi: 10.26355/eurrev_201806_15276.
16. Grant W.B., Fakhoury H.M.A., Karras S.N., Al Anouti F., Bhattoa H.P. Variations in 25-Hydroxyvitamin D in Countries from the Middle East and Europe: The Roles of UVB Exposure and Diet. Nutrients. 2019;11(9):2065. doi: 10.3390/nu11092065.
17. Feigenbaum J.J., Muller C., Wrigley-Field E. Regional and Racial In equality in Infectious Disease Mortality in U.S. Cities, 1900–1948. Demography. 2019;56(4):1371–1388. doi: 10.1007/s13524-019-00789-z.
18. Fairchok M., Schofield C., Chen W.J., Pugh M., Bigg H., Anold J.C., Millar E.V. Inverse Correlation between 25-OH Vitamin D Levels and Severity of Viral Respiratory Illness in Infants. J Infect Dis Epidemiol. 2017;3(2):030. doi: 10.23937/2474-3658/1510030.
19. Martineau A.R., Jolliffe D.A., Hooper R.L., Greenberg L., Aloia J.F., Bergman P. et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583. doi: 10.1136/bmj.i6583.
20. McGarrigle C.A., Ward M., Scarlett S., Kenny R.A. The contributions of the over 70s to Irish society: results from wave 5 of the Irish longitudinal study on ageing. Trinity College Dublin; 2020. Available at: https://tilda.tcd.ie/publications/reports/pdf/Report_Over70sContribution.pdf.
21. Fiona M. Vitamin-D and COVID-19: do deficient risk a poorer outcome? Lancet Diabetes Endocrinol. 2020;8(7):570. doi: 10.1016/S2213-8587(20)30183-2.
22. Guo C., Rosoha E., Lowry M., Borregaard N., Gombart A. Curcumininduces human cathelicidin antimicrobial peptide gen expression through ha vitamin D receptor-independent pathway. J Nutr Biochem. 2013;24(5):754–759. doi: 10.1016/j.jnutbio.2012.04.002.
23. Labg P.O., Aspinal R. Can We Translate Vitamin D Immunomodulating Effect on Innate and Adaptive Immunity to Vaccine Response? Nutrients. 2015;7(3):2044–2060. doi: 10.3390/nu7032044.
24. White J.H. Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord. 2012;13(1):21–29. doi: 10.1007/s11154-011-9195-z.
25. Каронова Т.Л., Вашукова М.А., Гусев Д.А., Головатюк К.А., Гринева Е.Н. Витамин D как фактор повышения иммунитета и снижения риска развития острых респираторных вирусных инфекций и COVID-19. Артериальная гипертензия. 2020;26(3):295–303. doi: 10.18705/1607-419X-2020-26-3-295-303.
26. Lang P.O., Samaras N., Samaras D., Aspinall R. How important is vitamin D in preventing infections? Osteoporos Int. 2013;24(5):1537–1553. doi: 10.1007/s00198-012-2204-6.
27. Громова О.А., Торшин И.Ю., Фролова Д.Е., Лапочкина Н.П., Лиманова О.А. О противовирусных эффектах витамина D. Медицинский совет. 2020;(3):152–158. doi: 10.21518/2079-701X-2020-3-152-158.
28. Gruber-Bzura B.M. Vitamin D and Influenza-Prevention or Therapy? Int J Mol Sci. 2018;19(8):2419. doi: 10.3390/ijms19082419.
29. Di Rosa M., Malaguarnera M., Nicoletti F., Malaguarnera L. Vitamin D3: a helpful immune-modulator. Immunology. 2011;134(2):123–139. doi: 10.1111/j.1365-2567.2011.03482.x.
30. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–1773. doi: 10.1126/science.1123933.
31. Van Belle T.L., Gysemans C., Mathieu C. Vitamin D in autoimmune, infectious and allergic diseases: A vital player? Best Pract Res Clin Endocrinol Metab. 2011;25(4):617–632. doi: 10.1016/j.beem.2011.04.009.
32. Sadeghi K., Wessner B., Laggner U., Ploder M., Tamandl D., Friedl J. et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006;36(2):361–370. doi: 10.1002/eji.200425995.
33. Christakos S., Ajibade D.V., Dhawan P., Fechner A.J., Mady L.J. Vitamin D: Metabolism. Endocrinol Metab Clin North Am. 2010;39(2):243–253. doi: 10.1016/j.ecl.2010.02.002.
34. Jeng L., Yamshchikov A.V., Judd S.E., Blumberg H.M., Martin G.S., Ziegler T.R., Tangpricha V. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009;7:28. doi: 10.1186/1479-5876-7-28.
35. Agier J., Efenberger M., Brzezinska-Blaszczyk E. Cathelicidin impact on inflammatory cells. Cent Eur J Immunol. 2015;40(2):225–235. doi: 10.5114/ceji.2015.51359.
36. Gal-Tanamy M., Bachmetov L., Ravid A., Koren R., Erman A., Tur-Kaspa R., Zemel R. Vitamin D: An innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology. 2011;54(5):1570–1579. doi: 10.1002/hep.24575.
37. Van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitaminD3: basic concepts. J Steroid Biochem Mol Biol. 2005;97(1–2):93–101. doi: 10.1016/j.jsbmb.2005.06.002.
38. Sun J. Vitamin D and mucosal immune function. Curr Opin Gastroenterol. 2010;26(6):591–595. doi: 10.1097/MOG.0b013e32833d4b9f.
39. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179(3):1634–1647. doi: 10.4049/jimmunol.179.3.1634.
40. Meehan M., Penckofer S. The role of vitamin D in the aging adult. J Aging Gerontol. 2014;2(2):60–71. doi: 10.12974/2309-6128.2014.02.02.1.
41. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020:395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
42. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585.
43. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
44. Boucher B.J. The problems of vitamin D insufficiency in older people. Aging Dis. 2012;3(4):313–329. Available at: https://pubmed.ncbi.nlm.nih.gov/23185713.
45. Cui C., Xu P., Li G., Qiao Y., Han W., Geng C. et al. Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: role of renin-angiotensin system. Redox Biol. 2019;26:101295. doi: 10.1016/j.redox.2019.101295.
46. Letko M., Munster V. Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV. bioRxiv. 2020;22:2020.01.22.915660. doi: 10.1101/2020.01.22.915660.
47. Hanff T.C., Harhay M.O., Brown T.S., Cohen J.B., Mohareb A.M. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations. Clin Infect Dis. 2020;71(15):870–874. doi: 10.1093/cid/ciaa329.
48. Helming L., Böse J., Ehrchen J., Schiebe S., Frahm T., Geffers R. et al. 1alpha, 25-Dihydroxyvitamin D3 is a potent suppressor of interferon gammamediated macrophage activation. Blood. 2005;106(13):4351–4358. doi: 10.1182/blood-2005-03-1029.
49. Rashedi J., Mahdavi Poor B., Asgharzadeh M. Vitamin D3 Administration to Patients with Confirmed COVID-19. Iran J Public Health. 2020;49(S1):141–142. doi: 10.18502/ijph.v49iS1.3690.
50. Ghavideldarestani M., Honardoost M., Khamseh M.E. Role of Vitamin D in Pathogenesis and Severity of COVID-19 infection. 2020. doi: 10.20944/preprints202004.0355.v1.
51. Kuba K., Imai Y., Penninger J.M. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol. 2006;6:271–276. doi: 10.1016/j.coph.2006.03.001.
52. Xie X., Chen J., Wang X., Zhang F., Liu Y. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78(19):2166–2171. doi: 10.1016/j.lfs.2005.09.038.
53. Grant W.B., Lahore H., McDonnell S.L., Baggerly C.A., French C.B., Aliano J.L., Bhattos H.P. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020;12(4):988. doi: 10.3390/nu12040988.
54. Autier P., Mullie P., Macacu A., Dragomir M., Boniol M., Coppens K. et al. Effect of vitamin D supplementation on non-skeletal disorders: A systematic review of meta-analyses and randomized trials. Lancet Diabetes Endocrinol. 2017;5(12):986–1004. doi: 10.1016/S2213-8587(17)30357-1.
55. Lips P., Cashman K.D., Lamberg-Allardt C., Bischoff-Ferrari H.A., Obermayer-Pietsch B., Bianchi M.L. Current vitamin D status in European and Middle East countries and strategiest o prevent vitamin D deffciency: a position statement of the European Calcifed Tissue Society. Eur J Endocrinol. 2019;180(4):23–54. doi: 10.1530/EJE-18-0736.
56. Cho N.H., Shaw J.E., Karuranga S., Huang Y., da Rocha Fernandes J.D., OhlroggeA.W., Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence or 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. doi: 10.1016/j.diabres.2018.02.023.
57. Malinovschi A., Masoero M., Bellocchia M., Ciureda A., Solidoro P., Mattei A. et al. Severe vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patients. Respir Res. 2014;15(1):131. doi: 10.1186/s12931-014-0131-0.
58. Kim H.J., Jang J.G., Hong K.S., Park J.K., Choi E.Y. Relationship between serum vitamin D concentrations and clinical outcome of communityacquired pneumonia. Int J Tuberc Lung Dis. 2015;19(6):729–734. doi: 10.5588/ijtld.14.0696.
59. Naghshtabrizi B., Borzouei S., Bigvand P., Seifrabiei M.A. Evaluation of the Relationship between Serum 25-Hydroxy Vitamin D and Hypertension in Hamadan, Iran-A Case Control Study. J Clin Diagn Res. 2017;11(7):LC01–LC03. doi: 10.7860/JCDR/2017/25522.10187.
60. Grober U., Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol. 2012;4(2):158–166. doi: 10.4161/derm.20731.
61. Hastie C.E., Mackay D.F., Ho F., Celis-Morales C.A., Katikireddi S.V., Niedzwiedz C.L. et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr. 2020;14(4):561–565. doi: 10.1016/j.dsx.2020.04.050.
62. Claire E.H., Jill P., Naveed S. Short Communication: Vitamin D and COVID-19 infection and mortality in UK Biobank. medRxiv. 2020. doi: 10.1101/2020.06.26.20140921.
63. Alipio M. Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19). SSRN Electron J. 2020. doi: 10.2139/ssrn.3571484.
64. Torjesen I. Covid-19: Public health agencies review whether vitamin D supplements could reduce risk. BMJ. 2020;369:m2475. doi: 10.1136/bmj. m2475.
65. Sabetta J.R., DePetrillo P., Cipriani R.J., Smardin J., Burns L.A., Landry M.L. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS One. 2010;5(6):e11088. doi: 10.1371/journal.pone.0011088.
66. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77(1):204–210. doi: 10.1093/ajcn/77.1.204.
67. van Groningen L., Opdenoordt S., van Sorge A., Telting D., Giesen A., de Boer H. Cholecalciferol loading dose guideline for vitamin D-deficient adults. Eur J Endocrinol. 2010;162(4):805–811. doi: 10.1530/EJE-09-0932.
68. Wimalawansa S.J. Global epidemic of coronavirus-COVID-19: What we can do to minimize risks. Eur J Biomed Pharm Sci. 2020;7(3):432–438. Available at: https://www.researchgate.net/publication/340102912_Global_epidemic_of_coronaviruses–COVID-19_What_can_we_do_to_minimize_risks_-_EJBPS.
69. Grant W.B., Al Anouti F., Moukayed M. Targeted 25-hydroxyvitamin D concentration measurements and vitamin D3 supplementation can have important patient and public health benefits. Eur J Clin Nutr. 2020;74(3):366–376. doi: 10.1038/s41430-020-0564-0.
70. Ross A.C., Manson J.E., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K. et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–58. doi: 10.1210/jc.2010-2704.
71. Grant W.B., Karras S.N., Bischo-Ferrari H.A., Annweiler C., Boucher B.J., Juzeniene A. et al. Do studies reporting U-shaped serum 25-hydroxyvitamin D-health outcome relationships reflect adverse effects? Dermatoendocrinol. 2016;8(1):e1187349. doi: 10.1080/19381980.2016.1187349.
72. Martineau A.R., Jollie D.A., Greenberg L., Aloia J.F., Bergman P., Dubnov-Raz G. et al. Vitamin D supplementation to prevent acute respiratory tract infections: individual participant data meta-analysis. Health Technol Assess. 2019;23(2):1–44. doi: 10.3310/hta23020.